Leman Biotech was among the top 150 in the 2022 Venture50 Sprout List by Zero2IPO Ventures (1945. HK). Out of over 3,000 participating companies, Leman Biotech distinguished itself with its strong technical capabilities and growth potential. The company's core technology, Meta 10, has been utilized to develop a new cancer immunotherapy that aims to treat solid tumors. Leman Biotech has received numerous accolades for this project, including recognition as a top 50 high-growth enterprise in the Greater Bay Area, an Excellence Award in the 2nd Southern University of Science and Technology "Sycamore Tree" International Innovation and Entrepreneurship Competition, and being a runner-up in the 14th China Shenzhen Innovation and Entrepreneurship Competition. The company was also among the top nine in the start-up group at the 11th China Innovation and Entrepreneurship Competition National Competition (Biomedicine), and received an Excellence Award. Notably, Leman Biotech is the only company from the Greater Bay Area and the only one in the top nine focused on cancer immunotherapy and cell and gene therapy (CGT) to be recognized in this national competition.
Since its establishment in 2006, Venture50 has maintained its original purpose of fostering innovation and promoting change. It has continued to support China's high-growth enterprises in their journey to resilience and growth. Over the years, Venture50 has seen countless startups grow from "sprouts" to "unicorns", and it has become a barometer for the investment value of these enterprises. As of October 2022, the event has attracted over 70,000 participating companies, helping raise more than US$35.8 billion. The three-year follow-up financing rate of Venture50-listed enterprises stands at 61%, with a listing rate of about 27.8%. Venture50 actively promotes venture capital to support the development of the industry and the economy, guiding more innovation and investment forces to create a fertile ground for entrepreneurship and innovation.
Leman Biotech is a clinical-staged cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and AI-driven drug R&D leader XtalPi. The company combines innovative metabolic reprogramming technology with cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. The core technology Meta 10 has the potential to cure solid tumors, as demonstrated in the published research in the top academic journal Nature Immunology, and has PCT patents in 56 countries and regions, covering major economies in the world. The company has a highly qualified R&D team, with over 70% of its personnel having graduated from esteemed Chinese and international universities and holding extensive industrial experience. Several of Leman Biotech's R&D pipelines are in advanced stage of development, including a metabolically armed CAR-T cell therapy in IIT clinical research stage. In December 2021, just half a year after its inception, Leman Biotech completed a successful angel round of financing, raising nearly $11 million, with plans for further financing underway. Leman Biotech is committed to finding solutions to the bottlenecks in cancer immunotherapy, improving the response rate and efficacy, and making unremitting efforts to achieve the ultimate goal of curing cancer.
